Low molecular weight heparin (60 mg daily) significantly reduced the frequency of deep vein thrombosis compared to placebo in elderly medical in-patients (3% vs 9%, p=0.03).
RCT (n=270)
Double-blind
randomized
Absolute Event Rate: 3% vs 9%
p-value: p=0.03
Two hundred and seventy patients over 65 years were included in a placebo-controlled randomized double-blind trial to determine whether a small dose of a low molecular weight (LMW) heparin prevents the occurrence of deep vein leg thrombosis (DVT) diagnosed by 125I fibrinogen scanning. LMW heparin (60 mg daily) significantly reduced the frequency of DVT from 9 to 3 percent (p = 0.03). Adverse drug reactions did not differ significantly between the 2 groups, except for the injection site hematomas that were more frequent in the LMW heparin group. In conclusion, LMW heparin appears of value in preventing the occurrence of DVT in an unselected elderly in-patient population.
Dahan et al. (Tue,) conducted a rct in Deep vein thrombosis prevention (n=270). Low molecular weight (LMW) heparin vs. Placebo was evaluated on Occurrence of deep vein leg thrombosis (DVT) diagnosed by 125I fibrinogen scanning (p=0.03). Low molecular weight heparin (60 mg daily) significantly reduced the frequency of deep vein thrombosis compared to placebo in elderly medical in-patients (3% vs 9%, p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: